Roger Pomerantz, ContraFect CEO (via X-Vax)
December 20, 2022 11:09 AM EST
R&D

Blam­ing place­bo re­sponse for 'un­in­ter­pretable' PhI­II re­sults, Con­tra­Fect calls for new an­tibi­ot­ic study

Amber Tong

Hav­ing spent the past few months comb­ing through the da­ta from a Phase III tri­al that it stopped for fu­til­i­ty, Con­tra­Fect con­clud­ed that it still …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times